immuno-oncology

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  

immuno-oncology
Dec 20, 2024, 22:35 | Blog
Jennifer S. Buell: Transforming cancer care through innovation in immuno-oncology
Jennifer S. Buell, President and Chief Executive Officer at MiNK Therapeutics, posted the following on…
Nov 9, 2024, 20:04 | Blog
Toni Choueiri on the Flexibility of Therapies Beyond PD-1 Inhibitors
Toni Choueiri, Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, shared…
Nov 2, 2024, 19:05 | Insight
Deridre Kelly: Anti–PD-L1 and TKI in anaplastic thyroid cancer
Deridre Kelly, Medical Oncologist at Mater Misericordiae University Hospital, shared a post on X: "Immuno…
Oct 29, 2024, 21:00 | Positive
Steven O'Day: At the Forefront of Immunotherapy
Dr. Steven O'Day, an immunotherapy pioneer and medical oncologist, is the Chief Medical Officer at…
Oct 14, 2024, 14:37 | Blog
Society for Immunotherapy of Cancer - Experience the latest in Immuno Oncology science at SITC 2024
Society for Immunotherapy of Cancer shared on X: '' Experience the latest in Immuno Oncology…
Oct 9, 2024, 07:58 | Blog
Last chance to register for ESMO Immuno 24 in Geneva - ESMO
ESMO - European Society for Medical Oncology posted the following on LinkedIn: “ESMO Immuno 24:…
Oct 3, 2024, 07:42 | Societies
The early registration deadline for ESMO Immuno24 is fast approaching
ESMO shared on LinkedIn: "ESMO Immuno24: The early registration deadline is fast approaching! Connect with…
Sep 28, 2024, 06:59 | Blog
Shubh Goel: AstraZeneca’s ambition in oncology aims for a future where cancer is no longer a cause of death
Shubh Goel, VP and US Franchise Head, Immuno-Oncology and GI Tumors at AstraZeneca, shared a post…
Sep 2, 2024, 08:40 | Blog
David Braun: We can make a personalized vaccine to target those tumor-specific antigens
Dana-Farber Cancer Institute shared a post on X: “'If we can identify neoantigens specific to…
Aug 25, 2024, 12:48 | Blog
The development of multimodal AI for clinical decision making in immunotherapy - NCI Systems Biology
NCI Systems Biology shared a post on X: "On Aug. 29 at 2:30 pm ET, Anant…
Aug 10, 2024, 19:12 | Societies
Register for the SITC Immuno-oncology Drug Development Summit in Boston
Society for Immunotherapy of Cancer (SITC) shared on X: "Register for the SITC Immuno-oncology Drug…
Aug 5, 2024, 15:54 | Career
Shivan Sivakumar: I am celebrating being at University of Birmingham for a year
Shivan Sivakumar, Associate Professor in oncology at the University of Birmingham, shared on X: "This…
Aug 3, 2024, 03:01 | Blog
Belén Garijo on Q2 results from Merck
Belén Garijo shared a post on LinkedIn: "We published our Q2 results today! Earlier this…
Jul 31, 2024, 09:17 | Blog
New Lung Cancer Considered episode, the use of ICIs in the treatment of molecular driven NSCLC
IASLC shared on X: "In this Lung Cancer Considered episode, Narjust Florez and 2 esteemed…
Jul 28, 2024, 08:50 | Insight
Novartis collaborates with Dren Bio to discover and advance novel antibody-based immune cell engagers
Fiona Hamilton Marshall, President of the Novartis Institute for BioMedical Research, shared on LinkedIn: “I’m…
Jul 26, 2024, 14:16 | Blog
2024 Multi-omics Meeting in Australia - Society for Immunotherapy of Cancer
Society for Immunotherapy of Cancer (SITC) shared a post on X: "Connect with global researchers…
Jul 19, 2024, 14:44 | Blog
"What’s Next for Immunotherapies?" by Anas Younes
Anas Younes shared a post on LinkedIn: Immunotherapies Immunotherapies "My interview with Mark Cobbold, Senior…
Jul 19, 2024, 02:00 | Blog
I ask Agenus to consider Armenia as the first country to register the BOT/BAL combination: Gevorg Tamamyan
"~20% ORR and 90% alive at 6 months in comparison to ZERO! How many patients…
Jul 18, 2024, 15:20 | Drugs
Our commitment to seek all possible pathways to make BOT/BAL available to patients is unwavering: Steven O'Day, Agenus CMO
Agenus shared on LinkedIn: "Today, we announced the outcomes of our End-of-Phase 2 meeting and…
Jul 14, 2024, 21:15 | Blog
Sumanta K. Pal: Excellent use of Twitter polls to reconcile tough clinical scenarios
Sumanta K. Pal shared a post on X: ''Brilliant insights from Tom Powles, Barts Cancer Institute.…
Jul 14, 2024, 07:19 | Insight
Immuno-oncologic profiling of pediatric brain - Hawkins Lab
Hawkins Lab shared a recent paper on X, titled "Immuno-oncologic profiling of pediatric brain tumors reveals…
Jul 10, 2024, 05:18 | Insight
APEIRON Biologics to be Acquired by Ligand Pharmaceuticals for USD 100 Million
APEIRON Biologics AG (“APEIRON”), a leading Austrian biotech company, today announced that its shareholders have…
Jul 7, 2024, 17:43 | Insight
Jarushka Naidoo: ctDNA+ associates with outcomes in stage III unresectable NSCLC
Jarushka Naidoo shared a post on X: “ctDNA+ in consolidation IO trial (BTCRC 16-081) associates…
Jun 27, 2024, 12:44 | Societies
Discuss the future of immuno-oncology with Agenus at ESMOGI24
Agenus shared on LinkedIn: "If you are a physician attending ESMOGI24 in Munich from June…
Jun 27, 2024, 09:10 | Insight
The promise of immuno-oncology in the neoadjuvant setting - ESMO
The European Society for Medical Oncology (ESMO) shared on LinkedIn: “The promise of immuno-oncology in…
Jun 18, 2024, 23:25 | Insight
The future of immuno-oncology discussion with Agenus at ESMO GI 2024
Agenus shared a post on LinkedIn: “Are you a physician attending ESMO GI 24? Join…
Jun 11, 2024, 15:17 | Blog
Julian Ashby: Deep preclinical characterization is essential to increase the chances of success in clinical trials
Julian Ashby, Product Marketing Manager at LUMICKS, shared on LinkedIn: “Each year, companies use tens…
Jun 4, 2024, 05:09 | Insight
Join us in Chicago to discuss the future of immuno-oncology - Agenus
Agenus shared a post on LinkedIn:  “Are you a physician attending ASCO24? Join us in…
May 1, 2024, 13:27 | Blog
Jennifer Marks: Reconsideration of IO in the inpatient setting
Jennifer Marks, Hematologist, Oncologist at MedStar Georgetown University Hospital, shared on X/Twitter: "Poster presentation on reconsideration…
Apr 23, 2024, 23:33 | Insight
Narjust Florez: Jessica Donington dissects adjuvant Immuno-Oncology in lung cancer
Narjust Florez shared a post on X: “Jessica Donington dissects adjuvant Immuno-Oncology in lung cancer.…
Apr 22, 2024, 10:32 | Blog
Narjust Florez: Dr. Julia Rotow discussed the role of IO in patients with target mutations
Narjust Florez shared a post on X: "IO and target therapy? Dr. Julia Rotow discussed…
Apr 19, 2024, 05:17 | Insight
Dina Schneider: Excited about our recent publication on Armored TGFBRIIdn ROR1-targeting CAR T cells for solid tumors
Dina Schneider, Director of Immuno Oncology and Cell Therapy at Lentigen Technology, shared on LinkedIn:…
Apr 4, 2024, 14:40 | Career
Nick Slack: I'm excited and humbled to announce my new role as Chairman and CEO of The START Center for Cancer Research
Nick Slack, Chairman and CEO of The START Centre for Cancer Research, shared on LinkedIn:…
Mar 28, 2024, 03:20 | Blog
Roberto Iacovelli: Thrilled to announce that TIDE-A trial is finally out on European Urology
Roberto Iacovelli, Associate Professor of Medical Oncology at Sacro Cuore Catholic University of Rome, shared on…
Mar 24, 2024, 13:47 | Career
Jean-Charles Soria: Thank you to my American Association for Cancer Research colleagues for this humbling vote of confidence
Jean-Charles Soria, SVP and Oncology Therapeutic Area Head, shared Amgen Oncology's post on LinkedIn and…
Jan 18, 2024, 15:12 | Blog
Maria Natalia Gandur Quiroga: Immuno-Oncology Advances in Genitourinary Cancers
Maria Natalia Gandur Quiroga shared a post on LinkedIn: "Immuno-Oncology Advances in Genitourinary Cancers: Introduction:…
Jan 9, 2024, 09:37 | Blog
“The Immuno-Oncology Curve” with Dr. Steven O’Day – Guests are Alexa Morell, Marianne Pearson and Andrew Wortmann
Steven O’Day, the Chief Medical Officer of Agenus, shared on LinkedIn: "Happy New Year! I’m…
Dec 18, 2023, 21:17 | Insight
Anthony Zamora: How advancements in sequencing technologies and bioinformatics pipelines have advanced our ability to identify cancer neoantigens
Anthony Zamora, Assistant Professor at the Medical College of Wisconsin, announced on LinkedIn: "Happy to…
Nov 28, 2023, 16:14 | Blog
“The Immuno-Oncology Curve" with Dr. Steven O'Day - Guest is Alexander (Lex) Eggermont
Steven O'Day, the Chief Medical Officer of Agenus, shared on LinkedIn: "I’m excited to announce…
Nov 20, 2023, 10:30 | Insight
Steven O'Day: I am thrilled to announce the upcoming launch of “The Immuno-Oncology Curve”
Steven O'Day, the Chief Medical Officer of Agenus, shared on LinkedIn: "I am thrilled to…
Nov 17, 2023, 16:24 | Drugs
Caroline J Loew: We’re excited to launch Mural Oncology
Caroline J Loew, CEO of Mural Oncology, shared Mural Oncology's post on LinkedIn adding: "We’re…
Nov 17, 2023, 13:59 | Insight
Revolutionizing Cancer Immunotherapy: Next-Gen CTLA-4 Targeting and Combination Therapies
Dive into the groundbreaking research published in "Oncology Immunology" (2023), where leading scientists Nils-Petter Rudqvist,…
Sep 24, 2023, 18:03 | Blog
Pashtoon Murtaza Kasi: The imagery at RareCyte Incorporated will blow your mind.
Quoting Pashtoon Murtaza Kasi, Oncologist and Researcher at Weill Cornel Medicine and New York- Presbyterian…
Sep 22, 2023, 17:54 | Blog
Together, we're shaping the future of healthcare! - IMAGIO Project
Quoting IMAGIO Project on LinkedIn: "The IMAGIO Consortium is composed by top experts in the…
Sep 12, 2023, 18:48 | Blog
Eric Deutsch: The countdown begins as ImmunoRad2023 7th edition fast approaches.
Quoting Eric Deutsch, Head of the Gustave Roussy Radiotherapy Department, on LinkedIn: ''The countdown begins as…
Aug 22, 2023, 18:09 | Career
Beatrice Duvert: I’m happy to share that I’m starting a new position as an Associate Program Manager at Agenus!
Quoting Beatrice Duvert, Associate Program Manager at Agenus, on LinkedIn: "I’m happy to share that…
All: 46 Posts: 1 - 100
Special Coverage